

**Table S3.** Treatment Pattern of Patients With mCRPC Before mCRPC Diagnosis to Third-Line Treatment for the Population of Patients Who Were Not Metastatic Before mCRPC Diagnosis – Aggregated Data (n = 45)

<b>Before mCRPC, n (%)</b>		<b>First line, n (%)</b>		<b>Second line, n (%)</b>		<b>Third line, n (%)</b>			
ADT only	23 (51.1)	ABI or ENZA	9 (39.1)	DOC	2 (22.2)	LOSS	2 (100.0)		
				LOSS	7 (77.8)	LOSS	7 (100.0)		
		AA	7 (30.4)	ABI or ENZA	3 (42.9)	DOC	1 (33.3)	LOSS	2 (66.7)
						DOC	3 (42.9)	ABI or ENZA	1 (33.3)
				LOSS	1 (14.3)	LOSS	1 (100.0)		
						LOSS	1 (100.0)		
		DOC	7 (30.4)	ABI or ENZ	3 (49.2)	LOSS	3 (100.0)		
						LOSS	4 (57.1)	LOSS	4 (100.0)
		ADT + AA	19 (42.2)	ABI or ENZA	13 (76.5)	ABI or ENZA	1 (7.7)	DOC	1 (100.0)
						DOC	3 (23.1)	ABI or ENZA	2 (66.7)
LOSS	9 (69.2)					LOSS	1 (33.3)		
AA	1 (5.9)			ABI or ENZA	1 (100.0)	LOSS	1 (100.0)		
						LOSS	9 (100.0)		
DOC	5 (17.6)			ABI or ENZA	2 (40.0)	LOSS	1 (100.0)		
						Others	1 (100.0)		

				CAB	2 (40.0)	LOSS	2 (100.0)
				Others	1 (20.0)	Others	1 (100.0)
ADT + OC	3 (6.7)	ABI or ENZA	3 (100.0)	CAB	2 (66.7)	ABI or ENZA	1 (50.0)
						LOSS	1 (50.0)
				LOSS	1 (33.3)	LOSS	1 (100.0)

AA: first-generation anti-androgen (bicalutamide or flutamide); ABI: abiraterone; ADT: androgen deprivation therapy; CAB: cabazitaxel; DOC: docetaxel; ENZA: enzalutamide; LOSS: information lost in tracking; mCRPC: metastatic castration-resistant prostate cancer.